Furthermore, several anticancer treatments can cause hypophosphatemia, including ifosfamide, cisplatin, and tyrosine kinase inhibitors (TKI) such as imatinib, sunitinib, sorafenib, and regorafenib, as well as anaplastic lymphoma kinase (ALK) inhibitors and mammalian target of rapamycin (mTOR) inhibitors, and fibroblast growth factor receptor (FGFR) inhibitors (286, 287). The gene discussed is MTOR; the disease is hypophosphatemia.